Verastem traded at $1.13 this Friday July 1st, decreasing $0.03 or 2.59 percent since the previous trading session. Looking back, over the last four weeks, Verastem lost 13.08 percent. Over the last 12 months, its price fell by 71.17 percent. Looking ahead, we forecast Verastem to be priced at 1.10 by the end of this quarter and at 1.01 in one year, according to Trading Economics global macro models projections and analysts expectations.


Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Peers Price Day Year
AbbVie 153.80 0.64 0.42% 33.54%
AstraZeneca 10,820.00 12.00 0.11% 24.07%
Curis 0.94 -0.04 -4.50% -87.74%
Cytokinetics 41.00 1.71 4.35% 98.93%
Epizyme 1.48 0.01 0.68% -81.41%
Gilead Sciences 62.36 0.55 0.89% -10.01%
Immunogen 4.61 0.11 2.44% -28.30%
Incyte Corp 77.67 1.70 2.24% -7.07%
Laboratory Of America 240.94 6.58 2.81% -13.32%
Novartis 80.96 -0.69 -0.85% -4.25%
Pfizer 52.31 -0.12 -0.23% 31.66%
Roche Holding 321.00 -1.60 -0.50% -9.19%
TG Therapeutics 4.57 0.32 7.53% -88.61%
Verastem 1.13 -0.03 -2.59% -71.17%
Ziopharm Oncology 1.30 0.06 4.84% -50.76%

Indexes Price Day Year
USND 11128 99.11 0.90% -23.99%
US2000 1728 19.77 1.16% -25.07%

Verastem
Verastem, Inc. is a biopharmaceutical company. The Company is focused on developing and commercializing medicines to improve outcomes for patients with cancer. The Company operates in the segment of developing drugs for the treatment of cancer. The Company’s marketed and developing products include defactinib and VS-6766. Defactinib is an oral small molecule inhibitor of FAK and PYK2 that is being evaluated as a potential combination therapy for various solid tumors. It is engaged in running clinical trials in cancers where there are limited treatment options, including leukemia, lymphoma, lung cancer, mesothelioma, ovarian cancer, head and neck cancer, colorectal cancer and pancreatic cancer. VS-6766 is an inhibitor of the RAF/MEK signaling pathway. VS-6766 blocks both MEK kinase activity and the ability of RAF to phosphorylate MEK.